Tofacitinib in Recurrent GBM Patients

Part of paid clinical trials in Dallas, Texas.

Sponsor
University of Texas Southwestern Medical Center
Study ID
NCT05326464
Phase
PHASE3
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tofacitinib 10mg — DRUG
    10 mg given orally twice daily until evidence of progression, intolerance of treatment, withdrawal of consent, or death.

Study Details

The purpose of this study is to examine the effects of Tofacitinib in patients with recurrent Glioblastoma.

Key Dates

Start date
Oct 7, 2022
Status verified
Dec 2025
Primary completion
Jun 16, 2025
Completion
Jun 1, 2027

Study Design

Enrollment
17 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Tofacitinib 10 mg
    Participants will take the 10mg Tofacitinib twice daily until evidence of progression, intolerance of treatment, withdrawal of consent, or death.

Primary Outcome Measure

Progression-free survival (PFS) of the study cohort as defined by RANO criteria. [ Time Frame: Up to 2 years after study treatment ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Texas Southwestern Medical CenterDallasTexas75390-

Related coverage on Hipa.ai

Find similar trials in Dallas, TX

By condition
Brain cancer
By specialty
OncologyNeuro-oncology
By research site
University of Texas Southwestern Medical Center· Dallas, TX

Related Studies